What is a Revenue Catalyst Intel Card and what is inside it?

A Revenue Catalyst Intel Card is a self-contained prospecting brief that combines a live buying signal, account relevance to your ICP, named contacts with double-verified LinkedIn and email, and a recommended outreach play - built so a rep can act in under 5 minutes. Each card pulls from one of our live data sources (FDA approvals, SEC filings, clinical trial milestones, funding rounds, exec moves, conference abstracts) and gets scored against your customer-specific ICP, install base, and territory. The same six-part format powers both Sales Intel Reports (monthly, tabbed by territory) and Conference Intel Reports (per event, tabbed by conference day). Cards are assembled by AI agents and verified by HCLS domain experts before delivery.

What are AI agents for life sciences sales teams?

AI agents are autonomous software systems that monitor market signals continuously - FDA approvals, SEC filings, clinical trial milestones, funding rounds, hiring surges, conference announcements, and more - then enrich and score those signals against your ICP, territory, and CRM data. Revenue Catalyst's agents are built on the latest frontier AI models, tuned by HCLS commercial operators with 50+ years of combined experience, and run a dedicated fact-check pass on every claim and contact before delivery. Your reps receive Intel Cards with named decision-makers, outreach hooks, and recommended next steps - no queries to write, no manual research required. Each cycle the agents get sharper: they remember what your team acted on, what was flagged as noise, and what your ICP looks like in practice - so monthly reports become more precise as the engagement matures.

What's the difference between using AI chat tools (ChatGPT, Claude.ai, Copilot) and AI agents for sales prospecting and account research?

AI chat tools (ChatGPT, Claude.ai, Microsoft Copilot, Gemini) require a human to ask the right question, paste in the right context, evaluate the answer, and copy the output to the next step - powerful but still manual. They also have no memory between sessions - every prospecting query starts from a blank slate. A rep researching one account through ChatGPT still spends 30-60 minutes, has no built-in fact-check, and walks away with scattered answers rather than a cohesive brief. AI agents like Revenue Catalyst's run autonomously and persistently: they pull signals from live data sources every cycle, score every account in your territory against your ICP without prompting, fact-check every claim and contact against public sources, and stitch the output into a single Intel Card per account - the signal, the named contacts (some your reps will already know, which validates the new ones), the hiring picture, the warm-introduction path, and the recommended hook. Cumulative memory across cycles: the agent remembers what it surfaced last month, what your team acted on, and what was flagged as noise. Chat tools answer one question at a time. Agents do the entire research workflow across your full territory, continuously.

How is Revenue Catalyst different from ZoomInfo, Apollo, or Zymewire?

ZoomInfo, Apollo, and Zymewire sell seat-based access to a database that your reps then have to research themselves. Revenue Catalyst delivers the finished research - a monthly Intel Card (interactive HTML report) with the named contacts, the dated signals, and the recommended outreach already mapped to specific accounts. There is nothing for reps to query and no SQL to write; they open the report and act. Pricing starts at a $2,500 Proof of Concept versus the $15K-$60K/yr seat licenses typical of the database vendors. The trade-off is fewer total contacts but each one is current and tied to a real, dated buying signal.

Can I see a sample Intel Card before I buy?

Yes. The Intel Cards section on revenuecatalyst.io shows four sample Sales Intel cards - an Expansion signal at Genentech / Roche, a Net New Prospect at Crescent Biopharma, a Target HCP / KOL on Dr. Sarah Chen, and a Deep Dive account dossier - plus a Conference Intel Agent example from AACR (286 sessions, 59 commercial-relevant, 93 named contacts). Each card shows what your reps actually receive: the buying signal, account context, named contacts with verified email and LinkedIn, the warm-introduction path, and a recommended outreach hook.

How accurate is Revenue Catalyst's contact data?

Revenue Catalyst verifies every contact at the moment of report delivery, not from a months-old crawl. For each named contact: LinkedIn profile is checked for current employer and title; business email passes multi-stage verification (pattern match, SMTP check, secondary enrichment); and the source link (LinkedIn URL or press citation) ships with the contact so your rep can audit it in seconds.

How quickly can we see results?

Your first report is delivered within a week of kickoff - no integration, no onboarding delays. From there, the agent gets sharper as it learns your ICP, install base, and territory structure. One analytical instruments client went from zero outbound pipeline to 43 qualified opportunities in 2.5 months. A protein analysis company saw a 56% cold email open rate within the first campaign cycle. Because the agent runs autonomously, your team starts every week with fresh, territory-ready intelligence instead of spending hours on manual research. For Conference Intel Reports, the action plan ships before the conference opens so your team walks in with a ranked poster hit list and named-presenter outreach hooks.

How much do AI agents for life sciences cost?

Sales Intel Agents are $3,500/mo Standard or $5,000/mo Premium per product line, with graduated volume discounts for companies with multiple product lines. Conference Intel Agents are $1,500 single, $3,750 3-pack (save 17%), or $5,000 5-pack (save 33%). Annual commitments save 20%. Build + Transfer (own the agent stack) is $25,000-$35,000 per product line one-time plus $1,500/mo advisory. Active Sales Intel subscribers receive 20% off any Conference Intel package. No lock-in contracts on any tier.

How does Revenue Catalyst protect our data and prevent AI training on it?

Your data stays inside Revenue Catalyst's infrastructure - we run on our systems, not yours, with no IT integration on your end. Each customer gets an isolated workspace (separate Git repository) so your ICP, customer lists, and report feedback never touch another customer's project. The Anthropic account setting that lets Anthropic use inputs to train their models is turned off for all Revenue Catalyst work. Anthropic's standard 30-day input retention applies for safety and abuse monitoring, then deletes them. Anthropic itself maintains SOC 2 Type II, ISO 27001, and ISO 42001 across the infrastructure that powers our agents. Revenue Catalyst's own SOC 2 Type 1 and ISO 27701 are evaluating on a roadmap consistent with customer security requirements - we do not claim certifications we do not hold.

Will AI sales agents replace our SDRs?

No. Revenue Catalyst's agents replace the research and prep work that consumes 60-70% of an SDR's week, not the human relationship layer. In life sciences specifically, scientific credibility, regulatory awareness, and KOL judgment are the points where buyers decide whether to engage - those stay with your reps. The agents free your team to spend time on the conversations that close deals, not on opening 14 browser tabs to figure out who at a target account owns the buying decision and why now.

How do AI agents generate pipeline for HCLS companies?

Our Sales Intel agents follow a 5-stage pipeline: (1) data collection from live, cross-domain sources including regulatory databases, job boards, industry news feeds, financial filings, and clinical trial registries; (2) signal processing that filters thousands of data points through your ICP definition, install base, and territory map; (3) four parallel research agents running simultaneously - expansion signals, net-new prospects, target HCP/KOL, and a deep account dossier - each with domain-specific prompting built on 50+ years of HCLS experience; (4) a dedicated fact-check agent that independently verifies every figure, contact, and company detail against public sources; and (5) territory-ready HTML reports tabbed by rep, with a worldwide view for sales leadership. One client went from zero pipeline to 43 qualified opportunities in 2.5 months.

What are Conference Intelligence Agents?

Conference Intelligence Agents prepare your team for scientific conferences like AACR, ASCO, ASH, ASHG, SLAS, ASMS, and PEGS. Our AI scrapes every poster abstract from the conference proceedings, matches them against your product line and target accounts, and delivers a day-by-day action plan with a ranked poster hit list, named presenters with outreach hooks, competitive intelligence (which competitors are presenting and where your accounts overlap), and pre-conference mailer content for your marketing team. The result: your reps show up knowing exactly where to be and what to say, instead of scanning the program book in the hotel lobby. Pricing starts at $1,500 per product line per conference, with 3-pack (save 17%) and 5-pack (save 33%) options. Active Sales Intel subscribers receive 20% off any conference package.

How do I prepare my sales team for AACR / ASCO / ASH?

Revenue Catalyst's Conference Intel Agent ships a per-event action plan tabbed by conference day, including a poster hit list ranked by commercial relevance, named contacts (presenting authors, session chairs, target-company attendees), booth maps, and competitive intel on who else is exhibiting. Reps walk in with a scheduled day-by-day plan instead of an exhibitor PDF. Used at AACR, ASCO, ASH, ASHG, SLAS, ASMS, PEGS and similar shows. Reports ship before the conference opens, and active Sales Intel subscribers receive 20% off any conference package.

What buying signals matter for biotech and pharma sales?

The signals that actually predict purchase windows in biotech and pharma are clinical-trial phase transitions (especially Phase II to Phase III), PDUFA dates, FDA submissions and approvals, funding rounds, commercial-team hiring (VP Commercial, first CCO, expansion of field sales), platform-shift announcements, and conference data readouts. Revenue Catalyst's Sales Intel Agents monitor ClinicalTrials.gov, FDA filings, SEC filings, NIH grants, press releases, and job intelligence boards, then deliver named, dated signals tied to a specific buyer at a specific account - not a generic intent score. Each signal carries a source citation so your reps can verify the trigger before reaching out.

Where does Revenue Catalyst's data come from and how often is it refreshed?

Revenue Catalyst pulls from live, multi-domain data sources including FDA device clearances and drug approvals, SEC filings and earnings reports, ClinicalTrials.gov, NIH grants, conference proceedings (AACR, ASCO, ASH, ASHG, SLAS, ASMS, PEGS), industry news feeds, job intelligence platforms, LinkedIn, and AI-powered deep web research. Sources run continuously and reports refresh on each delivery cycle. For Sales Intel Reports, the agent runs nightly with built-in deduplication so stale intel never resurfaces. For Conference Intel Reports, the full conference program is scraped once and re-scored against your account list as updates publish. Every contact in every card carries source tags pointing to the originating LinkedIn profile, press release, FDA listing, or peer-reviewed publication. New sources are added as they become available.

Can AI agents integrate with my CRM and existing sales tools?

For Standard and Premium tiers, there is zero integration required - we cross-reference your install base and CRM exports, then deliver standalone HTML reports your team can open anywhere. No IT involvement, no security review, no software to install. For Build+Transfer customers running the agent stack on their own infrastructure, deeper CRM and data-source integrations can be scoped during the engagement. Build + Transfer deploys on your VPC or a dedicated single-tenant server with end-to-end encryption.

Is Revenue Catalyst HIPAA compliant?

Revenue Catalyst's Standard and Premium tiers run entirely on our infrastructure with zero footprint on your systems - no CRM access required, no PHI ever touches our pipeline. We work exclusively with publicly available commercial signals (FDA listings, SEC filings, ClinicalTrials.gov, press releases, LinkedIn profiles), so there is no HIPAA-regulated data in scope. For Build + Transfer clients who want full control, we deploy on your VPC or a dedicated single-tenant server with end-to-end encryption - your security team owns the deployment. CRM cross-reference is optional and only happens if you choose to share read-only API access or push key fields for matching. Reports are delivered via password-protected URLs hosted on revenuecatalyst.io that your team can share without IT setup, login provisioning, or security review. Revenue Catalyst does not currently sign HIPAA Business Associate Agreements under the Standard or Premium tiers. If your engagement requires PHI handling or a signed BAA, our Build+Transfer option deploys the agent stack on your own infrastructure where your security team owns the BAA path.

How does Revenue Catalyst handle GDPR for teams prospecting in Europe?

Revenue Catalyst processes only publicly available business contact information about scientists, executives, and commercial decision-makers at HCLS organizations - drawn from FDA approvals, SEC filings, ClinicalTrials.gov, NIH grants, conference proceedings (AACR, ASCO, ASH, etc.), public LinkedIn profiles, and corporate websites - under the legitimate interest lawful basis (GDPR Art. 6(1)(f)), the same basis used by major B2B sales intelligence vendors. We provide a public Privacy Notice describing our processing, sources, retention, and data subject rights; a Data Processing Addendum with 2021 EU Standard Contractual Clauses available on request for EU-targeting customers; a data subject rights process at privacy@revenuecatalyst.io (access, rectification, erasure, objection - 30-day response, 72-hour suppression); and we rely on the EU-US Data Privacy Framework for transfers, with SCCs as a backup safeguard. We do not process patient health information or any GDPR special-category data, and we do not claim a 'GDPR certification' (no such certification exists). Our customers act as independent controllers responsible for their own outreach lawful basis under ePrivacy/PECR rules where applicable.

How do you prevent AI hallucinations in sales intelligence?

Every report passes through a dedicated fact-check agent before delivery. This verification agent independently cross-checks every contact name, title, company detail, and market claim against public sources - SEC filings, FDA databases, ClinicalTrials.gov, LinkedIn, and company websites. Contacts include source tags showing exactly where each data point originated. If a claim cannot be verified, it gets flagged or removed - never guessed. Email contacts pass multi-stage verification (pattern match, SMTP check, secondary enrichment) before any name ships. On top of that, our HCLS commercial veterans review every report with the same judgment we used managing territories and running commercial teams. We catch things a generic system would miss because we have sold into these accounts ourselves.

What ROI should I expect from a Revenue Catalyst engagement?

Revenue Catalyst clients consistently see 5-20x ROI within the first quarter - driven by 40+ hours of analyst work replaced per rep per month, materially higher cold email open rates (56% vs. the 23% industry average), and faster pipeline build (one VC-backed biotech went zero-to-43 qualified opportunities in 2.5 months). At $3,500/mo for the Standard tier and a typical sales rep cost of $150K+ fully loaded, recovering 10 hours of research time per rep per week pays for the agent within weeks. The PoC structure ($2,500 credited toward subscription) is designed so you can measure your own ROI on real output before committing - if it does not drive action, you keep the report. Active subscribers report cumulative gains as the agent learns ICP, install base, and rep feedback patterns over each cycle.

What does a typical Revenue Catalyst onboarding and first-month workflow look like?

Week 1: 30-minute intake call to lock ICP, target accounts, and target signals; first Intel Card delivered as a password-protected interactive HTML report. Ongoing: feedback/tuning cycle - rep feedback is captured async and folded into the next run. Month 2 onward: monthly Intel Cards (Sales Intel Agents) or per-event Intel Cards (Conference Intel Agents). No CRM rip-and-replace, no integrations to build, no rep training - your team consumes the report in their browser. The agent gets sharper each cycle as it learns which signals you act on and which you flag as noise.

Do you cover diagnostics and medical device companies, or only biotech?

Yes. Revenue Catalyst Intel Cards are built for biotech, pharma, diagnostics, medical device, and life-science tools and instruments. CRO/CDMO and other adjacencies are evaluated case-by-case. The signals and contact roles change by vertical - FDA 510(k) clearances and IDN procurement for medical device; CLIA/CAP labs and reference-lab partnerships for diagnostics; FDA approvals and PDUFA dates for biotech and pharma - and the agent is configured per ICP at intake. The same Intel Card format works across verticals; the underlying signal mix and named-contact roles get tuned to your market.

What life science verticals do you work with?

We have built and run commercial teams in analytical instruments, flow cytometry, single-cell analysis, genomics, proteomics, diagnostics, digital health, pharma services, and medtech - at companies including Thermo Fisher, Sartorius, Bio-Rad, and multiple venture-backed startups. That operating experience is what makes the intelligence useful. We know which FDA approval is a buying signal versus noise, which conference talks indicate budget authority, and which hiring patterns signal expansion. The agents are prompted with that context, not generic templates. New verticals adjacent to HCLS (CRO services, lab informatics, scientific publishing) are evaluated case-by-case based on data-source overlap with our existing pipeline.

How does Revenue Catalyst compare to intent-data platforms like Bombora or 6sense?

Revenue Catalyst and intent-data platforms solve different problems. Bombora and 6sense aggregate web behavior signals across thousands of sites to identify accounts researching topics. Revenue Catalyst surfaces specific, dated buying events at named accounts - IND clearances, funding rounds, exec moves, conference activity, hiring surges - tied to your ICP and product line, with named contacts and a recommended outreach play. The two are complementary, not substitutes. Intent data tells you which accounts are in market; Revenue Catalyst tells your reps exactly what just happened, who to talk to, and what to say. Most HCLS commercial teams need the latter - life sciences buying cycles are signal-driven (regulatory milestones, clinical trial events, hiring at target functions), and broad intent data tends to be too noisy for life sciences accounts. If you already use Bombora or 6sense, our Intel Cards work alongside them as the action-ready layer.

Can Revenue Catalyst help with KOL identification and mapping?

Yes - KOL identification and mapping is core to our Target HCP/KOL Intel Cards (Premium tier). Our agents identify key opinion leaders, scientific advisors, and HCP champions tied to your priority accounts using a combination of publication history (peer-reviewed journals, ClinicalTrials.gov, NIH grant databases), conference activity (AACR, ASCO, ASH, ASHG, SLAS, ASMS, PEGS speaker rosters and abstracts), advisory board positions, and warm-introduction paths through your team’s LinkedIn network. Each KOL Intel Card includes the named clinician or scientist, their recent publications and presentations, current affiliations, the buying-decision context (who they influence, what they care about), and a recommended outreach angle tied to a specific recent piece of work. KOL Intel Cards are included in the Premium tier; Standard tier focuses on Expansion and Net-New Prospect cards across your territory.

Is Revenue Catalyst a fractional sales ops service or just an AI tool?

Both, depending on the engagement. Standard and Premium tiers are AI-agent subscriptions - you receive monthly Intel Reports your team acts on, with the agent stack run on our infrastructure. Many customers also engage our Rev Ops services (Prospecting, Demand Generation, Sales Operations) as a fractional layer alongside the agents - for example, having Revenue Catalyst run outreach campaigns directly off the Intel Cards instead of doing it in-house, or augmenting an existing sales ops function with CRM hygiene, pipeline analytics, and territory planning. This combined model works well for early-stage biotech and mid-market HCLS commercial teams that want commercial intelligence plus execution without hiring a 5-person ops team. Build + Transfer is the option for customers who want to own the agent stack outright on their infrastructure - we deploy, train, and transfer.

Winning Commercial Teams Are Going Agentic in 2026

AI Agents & Revenue Operations
for Healthcare and Life Sciences

Q: What services does Revenue Catalyst offer for HCLS commercial teams?

Revenue Catalyst provides AI agents and full-service revenue operations for healthcare and life sciences commercial teams. Sales Intel Agents deliver territory-specific signals, verified contacts, competitive intel, and outreach hooks in monthly HTML reports - zero IT required. Conference Intel Agents prepare teams for scientific conferences like AACR, ASCO, ASH, and PEGS with day-by-day poster hit lists, named presenters, and competitive overlays. Prospecting covers net-new outreach campaigns built off the Intel Card - verified contacts, sequenced messaging, and meetings booked. Demand Generation covers content, paid, and event motions tied to the same ICP signals the agents surface - LinkedIn, conference outreach, nurture sequences. Sales Operations covers CRM hygiene, pipeline analytics, and sales-cycle instrumentation so the signals the agents surface actually move through your funnel. Every service is built by HCLS operators with 50+ years of combined experience spanning IC to VP roles across sales, marketing, and customer success.

Better Intel. More Pipeline. Zero New Headcount.

Built by HCLS operators with deep domain expertise spanning IC to VP across sales, marketing, and customer success – we have lived the problems these agents and services solve.

Sales Intel Agents Conference Intel Agents Rev Ops Services

Trust

50+ years of HCLS commercial experience encoded into agent skills and memories

Engine

Latest frontier-model AI agents transforming real-time signals into actionable intelligence for your team

Validation

Every account, claim, and contact double-verified against public sources

Deliverable

Intel Cards with signals, narratives, contacts, and the hook aligned to your ICP and playbooks

Zero Footprint on Your Systems Agents Get Sharper with Your Feedback First Report in a Week

Why Now

Commercial teams deploying AI agents are pulling ahead. BCG reports AI leaders achieve 1.7× the revenue growth of laggards, with the gap widening quarterly.

Your team is manually tracking signals across dozens of sources

One agentic pipeline replaces dozens of manual searches

Regulatory approvals, SEC filings, clinical trials, funding rounds, executive moves, job postings, press releases, product launches, conference announcements, and partnership signals – pulled in parallel, scored against your ICP, and ready before your first meeting of the cycle.

Result: 2,400 evidence-matched leads for a single client

Salesforce reports 30% of HCLS sales effort fails to target the intended decision maker or leverage the appropriate messaging

Science-matched targeting changes the math

Prospects matched to their own publications, conference talks, and research grants. Every touchpoint references something real, not a template. Industry average cold email open rate is ~23%. Ours hit 56%.

Result: 56% open rate • 2.4x industry average

9% of life sciences execs see real returns on AI. The other 91% are still experimenting. We build the agents that put you in the 9%.

The window for first-mover advantage is now

McKinsey found only 6% of organizations capture real value from AI. The difference is not the technology. It is having operators who know your workflows build the system. We have done it 6 times in HCLS and counting.

Result: 43 new opps in 2.5 months from a standing start

Sources

BCG: AI Leaders Outpace Laggards (2025) McKinsey: State of AI (2025) Deloitte: Life Sciences Outlook (2026) Salesforce: HCLS AI Survey (2025) Bain: Commercial AI Winners (2025) ZS: Scaling AI in Pharma (2026)

What is an Intel Card?

Intelligence your rep can act on today in under 5 minutes. A Revenue Catalyst Intel Card is a self-contained prospecting brief that combines live buying signals, account relevance to your ICP, named contacts with double-verified LinkedIn and email, and a recommended outreach play. Lead lists, market intel, and generic AI each solve one piece; Intel Cards combine all three with the next-action play.

Signals

What just happened — funding round, IND clearance, exec move, hiring surge, conference abstract. Sourced + dated + linked.

Opportunity Sizing

M / L / XL tag with one-line context. Tells your rep at a glance whether this is a quick win, a multi-site land, or a major strategic account.

Key Contacts

Named decision-maker + LinkedIn + email + warm-intro path through your team’s network. Multi-stage verification before any name ships.

Net-New Prospect

Crescent Biopharma

Waltham, MA

Series B: $400M+ · Nov 2025 IND Cleared · Jan 2026 Hiring · 3 Roles

Why Now

Series B $400M+ (Nov 2025): capital deployed for clinical infrastructure. IND cleared Jan 2026: lead ADC candidate moving to first-in-human, vendor decisions imminent. Hiring 3 analytical roles: building CMC team from scratch – no legacy vendor lock-in.

Opportunity Size

M-L Greenfield build, no incumbent

Your Play

Rachel Torres is building CMC from scratch with no incumbent vendor. Your path in: a co-author from AACR is connected to a CMC advisor in Torres’s network. Crescent is presenting preclinical ADC data at AACR 2026 (April) and evaluating vendor partnerships through Q2.

Lead through the chain: “Rachel, [CMC Advisor] mentioned you’re building out analytical infrastructure for the ADC program. As you evaluate vendors ahead of AACR, happy to share how similar-stage biotechs have approached it.”

Key Contacts

Rachel Torres, Head of CMC

You ▶ AACR Co-Author ▶ CMC Advisor ▶ R. Torres 3rd *

LinkedIn ••••• r.torres@••••.com

Copy to CRM Note · Export Contacts CSV

Why Now

Account context tied to your ICP and the timing window that makes this signal actionable — this month, this quarter, this conference day.

Your Play

The exact action plus a persona-tailored opener your rep can lift straight into LinkedIn or email. References something real about the account, not a template.

CRM-Ready Output

One-click copy of card contents to your CRM Notes field. CSV export of all contacts with rep-assignment column for bulk import. No API, no integration, no IT involvement.

Sample Intel Cards

Each rep opens their territory tab and sees four card types – Expansion signals, Net-New prospects, and Target HCP/KOL targets – each with named contacts and a specific entry angle. Deep Dives add a comprehensive view of priority accounts with competitive landscape, named stakeholders, and specific hooks per buying initiative.

Expansion Signal

Genentech / Roche

South San Francisco, CA

Expansion · XL Hiring · 3 Open Roles Phase 3 Trials

Why Now

Expansion XL: $50B U.S. investment announced Jan 2026, 6+ new sites breaking ground (Oceanside biologics Q2). Hiring 3 open roles: analytical leads in Cambridge, Vacaville, and Oceanside. Phase 3 trials: bispecific antibody portfolio scaling analytical demand across manufacturing.

Opportunity Size

XL Multi-site expansion, existing install base

Your Play

Your West Coast rep has a direct LinkedIn connection to James Whitfield, who oversees analytical development across Genentech’s South San Francisco campus. With 6 new sites coming online – including Oceanside biologics breaking ground Q2 – manufacturing teams are making analytical software decisions now.

Lead with the warm intro: “James, [West Coast Rep] suggested I reach out – your SF team already runs [product] in discovery, and with Oceanside and Cambridge staffing up analytical leads, it might be worth a conversation before PEGS about extending across the new sites.”

Key Contacts

James Whitfield, VP, Analytical Development

You ▶ West Coast Rep ▶ J. Whitfield 2nd *

LinkedIn ••••• j.whitfield@••••.com

Copy to CRM Note · Export Contacts CSV

Net-New Prospect

Crescent Biopharma

Waltham, MA

Series B: $400M+ · Nov 2025 IND Cleared · Jan 2026 Hiring · 3 Analytical Roles

Why Now

Opportunity Size

M-L Greenfield build, no incumbent

Your Play

Key Contacts

Rachel Torres, Head of CMC

You ▶ AACR Co-Author ▶ CMC Advisor ▶ R. Torres 3rd *

LinkedIn ••••• r.torres@••••.com

Copy to CRM Note · Export Contacts CSV

Target HCP / KOL

Dr. Sarah Chen, MD, PhD

VP, Translational Medicine • Top-20 Biopharma

ASCO 2026 Speaker · May 2026 3 Publications · 2025-2026 KOL · Advisory Board

Why Now

ASCO 2026 speaker (May): presenting on translational biomarker strategies, pre-conference outreach window open. 3 publications 2025-2026: latest (Dec 2025, JCO) cited your competitor’s assay platform but flagged clinical sensitivity gaps. KOL / Advisory Board: influences platform decisions across her oncology network.

Opportunity Size

M Platform evaluation, potential site-wide adoption

Your Play

You are a direct LinkedIn connection to Dr. Chen. She is presenting at ASCO in May and chairing a companion diagnostics symposium at AACR in April – both are pre-conference outreach windows. Her most recent JCO paper cited your competitor’s assay platform but flagged limitations in clinical sensitivity – exactly what your platform solves.

Lead with the research: “Sarah, your JCO paper on companion diagnostic sensitivity for ADC patient selection was excellent. You flagged the exact limitation we’ve helped 3 oncology teams solve this year. I see you’re presenting at ASCO in May – would love to connect beforehand.”

Key Contacts

Dr. Sarah Chen, MD, PhD, VP, Translational Medicine

You ▶ Dr. Chen 1st *

LinkedIn ••••• s.chen@••••.com

Copy to CRM Note · Export Contacts CSV

Deep Dive

Regeneron Pharmaceuticals

9 sites · 18 new Phase 3 (2026) · 30+ named personas mapped

Strategic Priorities $14.3B FY2025 · 4 initiatives driving 2026 spend

Priority account selected by your sales leader. 9 sites across 2 countries, 18 new Phase 3 studies planned for 2026, 30+ named personas mapped by department and influence level, competitive landscape across three bispecific franchises, and entry points tied to a $2B greenfield build, 2,000+ new hires, and triple product launch.

$14.3B FY 2025 Revenue $5.9-6.1B 2026 R&D Guidance 9 Sites + 1 greenfield 18 New Phase 3 (2026)

VelociSuite Scaling $2B Greenfield Build Triple Bispecific Launch Cell Medicines R&D Digital Transformation $3B FUJIFILM Partnership

● R&D / Discovery ● Clinical ● Manufacturing ● Digital / IT ● Emerging

Antibody Discovery: VelociSuite platform scaling for 18 new Phase 3 programs, 50+ scientists hiring, $1.8B Tarrytown campus expansion (8 new buildings, 900K sqft)
Lab EquipmentReagents & ConsumablesAnalytical InstrumentsLab Automation
Clinical Pipeline: Lynozyfic approved (myeloma launch active), Odronextamab EU-approved (2nd US CRL, mfg issues), Fianlimab Phase 3 data expected 2026, Dupixent $4.9B Q4 (32% growth, peak >$20B/yr), 35K target enrollment
Clinical DiagnosticsBioanalyticalQC/QA PlatformsField Force Tools
Manufacturing Expansion: $2B Saratoga Springs greenfield (1,000 jobs, no incumbents), Rensselaer fill/finish scaling, $3B+ FUJIFILM Holly Springs partnership, Limerick EU hub (1,400 staff)
Bioprocess SystemsAnalytical InstrumentsContract Manufacturing
Strategic Moves: New EVP CDO/CTO for enterprise digital transformation (joined 2026), $275M Tessera gene editing partnership ($150M upfront), Cell Medicines R&D in Cambridge + Seattle (~150 staff from 2seventy bio acquisition)
Digital InfrastructureLab InformaticsCell & Gene Therapy

Key Personas 30+ stakeholders across 4 buying initiatives

Manufacturing & Supply Chain

$7B+ across 5 sites · 6 contacts

$2B Saratoga Springs greenfield with no incumbent vendors (groundbreaking Q1 2026). $3B+ FUJIFILM Holly Springs partnership coming online 2025-2026 with dual buying committee. Rensselaer fill/finish scaling for Lynozyfic + Dupixent + new launches. Three concurrent capacity programs reporting up to one P&L owner.

Rajesh A. · SVP, Fill/Finish & External Manufacturing

LinkedIn 10-K

Multi-site mfg scale-up · new launch capacity + greenfield buildout. Reference his Saratoga groundbreaking LinkedIn post as opener.

You ▶ Sarah K. (Acct Mgr) ▶ Peter S. (Head, CMC Reg) ▶ Rajesh A. 3rd *

Daniel R. · Global Procurement Mgr, Capital Equipment (Saratoga)

Job Post LinkedIn

Hiring NOW for the Saratoga buildout – vendor spec decisions happening as he ramps. First-mover wins the equipment categories.

You ▶ FUJIFILM Site Ops Lead ▶ Daniel R. 2nd *

+ 6 additional manufacturing personas mapped (site directors, validation lead, supply-chain ops, QA lead, packaging ops)

Antibody Discovery (Tarrytown VelociSuite)

$1.8B campus build · 10 contacts

VelociSuite platform scaling for 18 new Phase 3 programs in 2026. 50+ scientists hiring across antibody discovery, flow cytometry, and bioassay. $1.8B Tarrytown expansion – 8 new buildings, 900K sqft. Engage discovery leadership before new scientists default to whatever’s on the bench.

Lyndon M. · Exec Director, Research Initiatives, RGC

Genomics infrastructure + sequencing platforms across all therapeutic areas. Co-panelist at ASHG 2025 – live conference connection.

You ▶ ASHG 2025 Co-Panelist ▶ Lyndon M. 2nd *

Dr. Pamela H. · Director, Discovery Platform Engineering

LinkedIn Patent

Owns equipment + reagent stack decisions for the 50+ onboarding scientist wave. Lab automation + flow cytometry refresh in scope.

You ▶ Mike Z. (former Regeneron) ▶ Dr. Pamela H. 2nd *

+ 8 additional R&D personas mapped (assay leads, lab managers, postdoc PIs across antibody + cell biology)

Clinical & Companion Dx (Triple Bispecific Launch)

3 simultaneous launches · 7 contacts

Lynozyfic launched (myeloma), Odronextamab EU-approved (Ordspono), Fianlimab Phase 3 data expected 2026. Three franchises, three buying cycles, three companion-dx programs running in parallel. Biomarker expansion across 30+ clinical candidates; 18 new Phase 3 studies planned for 2026.

Jennifer H., PhD · VP, Precision Medicine

LinkedIn Conference

Assay platforms + companion dx + NGS for triple bispecific launch. Speaking at AACR 2026 – meet at booth.

You ▶ Sarah K. ▶ David P. (Dir Companion Dx) ▶ Jennifer H. 3rd *

Kavita N. · Sr. Director, Clinical Operations (Armonk)

LinkedIn Job Post

35K target enrollment across 18 P3 studies – bioanalytical + QC platform decisions consolidating now.

You ▶ Kavita N. 1st *

+ 6 additional clinical personas mapped (assay leads, regulatory, biomarker statistician, clinical data manager)

Digital Transformation

New EVP CDO/CTO mandate · 5 contacts

New EVP, Chief Digital Officer/CTO joined 2026 with enterprise-wide AI/ML and lab-informatics modernization mandate. Vendor selection window open now across lab informatics, greenfield digital infrastructure (Saratoga, Cell Medicines Cambridge/Seattle), and discovery analytics. Procurement signoff is centralizing under digital leadership.

Ryan S. · EVP, Chief Digital Officer / CTO

LinkedIn Press Release

Greenfield digital infra – vendor selection window open. Joined 2026 with executive mandate to refresh enterprise stack.

You ▶ Craig M. (Dir, Regeneron) ▶ Ryan S. 2nd *

Marcus T. · Director, Lab Informatics & Data Engineering

Owns ELN / LIMS / data-pipeline stack refresh tied to the discovery campus expansion.

You ▶ Craig M. ▶ Marcus T. 2nd *

+ 4 additional digital personas mapped (cloud architecture, AI/ML engineering lead, security ops, data platform lead)

Plays Competitive landscape · 7 sites · 3 entry windows

Competitive Landscape Bispecific + mfg overlap with named rivals

Franchise	Regeneron	Key Competitors	Market Signal
Myeloma (BCMA)	Lynozyfic (approved)	J&J Tecvayli, Pfizer Elrexfio	Regeneron claims best efficacy
Lymphoma (CD20)	Odronextamab (EU-approved as Ordspono)	Roche Columvi, AbbVie Epkinly	2nd US CRL (mfg) – competitors already launched
Melanoma (LAG-3)	Fianlimab + Libtayo (Phase 3)	BMS Opdualag	Early data suggests superior efficacy
Manufacturing	$7B+ expansion across 5 sites	–	No incumbents at greenfield sites

Recommended Strategy

Lynozyfic launched, fianlimab Phase 3 data imminent, odronextamab already approved in EU – three bispecific franchises driving simultaneous clinical ops, bioanalytical, companion diagnostics, and manufacturing expansion. Greenfield sites (Saratoga Springs, Cambridge/Seattle Cell Medicines) have no incumbent vendors in any equipment category. Engage procurement during buildout – once equipment is spec’d into facility design, switching costs become structural.

Site Opportunity Map $7B+ across 5 active build-outs

Site	Investment	Focus	Status
Tarrytown, NY	$1.8B	Campus expansion, 8 new buildings, 900K sqft	Active (184+ open roles)
Sleepy Hollow, NY	Acquired	Separate ~383K sqft campus (former NY Life), R&D overflow	Operational
Saratoga Springs, NY	$2B	Biologics + infectious disease mfg	Construction Q1 2026 (no incumbents)
Rensselaer, NY	Existing	Fill/finish: Dupixent, Libtayo + new launches	Scaling (35+ open roles)
Limerick, Ireland	$1B+	Bulk biologics API, global supply	Expanding (1,400 staff)
Holly Springs, NC	$3B+	FUJIFILM partnership, modular mfg	Coming online 2025-2026
Seattle, WA	Acquired	Cell Medicines ops (~150 staff, ex-2seventy bio)	Active (cell therapy R&D)

Entry Points 3 time-bound openings to use this month

Conference ASMS 2026 (May 31 – Jun 4, San Diego) – multiple Regeneron speakers. Pre-conference outreach window opens May. May 2026

Hiring 2,000+ new roles planned across 7 sites. Global Procurement Manager for facilities & capital equipment posted at Saratoga Springs – equipment spec decisions happening now. Active Now

Trigger FUJIFILM Holly Springs capacity online 2025-2026. Dual buying committee (Regeneron process dev + FUJIFILM site ops) – two independent entry points into a $3B+ partnership. 2025-2026

* Powered by your team’s LinkedIn networks (CSV import or Sales Nav TeamLink).

Sample cards based on real agent deliveries. Names and details are illustrative. Your cards are tailored to your products, territory, CRM, and ICP. Every card cross-references your CRM, external signals, your reps’ network, and your sales playbook. That is what makes it actionable, not just informational.

AI Agents and Services

Intel Cards are the building blocks. Reports are the deliverable. RC packages cards into two AI-agent-built reports: Sales Intel Reports (monthly, by territory) and Conference Intel Reports (per event, by day). Both ship as password-protected URLs – no IT setup, no seat licenses, no software to install.

The Engine

Your Autonomous Intelligence Pipeline

Five AI-powered stages that run end-to-end continuously without any lift from your team – aligned to your ICP and playbooks, tuned by 50+ years of HCLS operator judgment encoded into prompts, scoring weights, and fact-check standards, and sharpened through recursive self-improvement with each delivery cycle. Agents are the engine. Cards are the output. Operator judgment is what competitors can’t copy.

1 Live Data Sources

Cumulative · cross-domain coverage

Continuous, cross-domain monitoring across regulatory, market, talent, conference, and company-intelligence signals – synthesized through an AI-powered deep research and scraping pipeline.

Government & regulatory: FDA approvals and clearances, clinical trial registries, federal grant awards, patent and IP databases
Industry & market: SEC filings and earnings call transcripts, peer-reviewed publications, analyst coverage, market sizing reports
Talent & company: job posting analysis at target accounts, leadership transitions, headcount signals, press releases, product launches, partnership and M&A announcements, executive communications
Conferences: abstract and poster databases, exhibitor and sponsor directories, session programs, speaker rosters, pre- and post-conference content
Deep research pipeline: AI-powered scraping and synthesis across hundreds of additional web sources, with new sources added continuously as they become available

2 Signal Processing

Proprietary fit scoring · tuned per customer

AI filters thousands of raw signals through your ICP, customer context, and product playbook – surfacing only the highest-priority, most actionable intel for your team.

Signals ranked by relevance and actionability, with built-in deduplication so stale intel never resurfaces
Models, filters, and scoring tuned per customer and continuously improved based on your team’s feedback each cycle
Customer context cross-reference: every signal validated against your CRM, install base, prior interactions, and competitive map – so the right intel is routed to the right team

3 Parallel Research Agents

HCLS-tuned · 50+ years of operator judgment in the prompts

Sales: Expansion, Net New Prospect, Target HCP/KOL, and Deep Dive agents in parallel. Conference: tier classification (own / new biz / expansion / competitive watch) + must-visit flag.

Expansion Signals Agent: identifies growth triggers at existing and target accounts – lab buildouts, manufacturing expansions, technology transitions, leadership hires, competitive displacements
Net-New Prospect Agent: discovers companies not on your radar, ranked by ICP fit and signal strength, each with named contacts and entry angles
Target HCP / KOL Agent: identifies key opinion leaders, scientific advisors, and HCP champions tied to your priority accounts – publication trail, conference talks, advisory positions, and warm-introduction paths
Deep Dive Agent: full account dossier on your priority account – 15+ stakeholders across buying initiatives mapped by department and influence, competitive landscape, and outreach hooks per stakeholder

4 Fact-Check & Verification

Operator · HCLS veterans hand-polish every report

A dedicated agent cross-checks every claim against public sources. Contacts pass multi-stage verify (pattern, SMTP, secondary enrichment). No hallucinated names.

Every claim traced to a verifiable public source: regulatory filing, press release, job posting, or clinical trial record
Contacts pass multi-layer verification (LinkedIn-first · email pattern · SMTP · secondary enrichment) before any name ships
Cumulative memory across reports – the agent remembers what it surfaced last month, what your team acted on, and what was flagged as noise, so each cycle is smarter than the last

5 Hosted, Tabbed Report

40+ hrs/mo · analyst work replaced per rep

Branded report tabbed by territory (Sales) or conference day (Conference) – hosted at a password-protected URL your team can share without logins or IT setup.

Sales: each rep gets their own territory tab; sales leadership gets a Summary view with cross-territory opportunities and coverage gaps; Deep Dive tab covers your priority account end-to-end
Conference: each conference day gets its own tab with sessions, must-visit posters, walking-path picks, and named-presenter outreach hooks
Hosted at a password-protected URL on revenuecatalyst.io – delivered within a week, share with your team, no login, no software, no IT involvement

Zero Footprint on Your Systems: Standard and Premium tiers run entirely on our infrastructure. No IT involvement, no security review, no integrations required – your team just receives the report. For Build + Transfer clients who need full control, we deploy on your VPC or a dedicated single-tenant server with end-to-end encryption.

Compare all three side-by-side

Sales Intel Agents Sales Intel Report Monthly tabbed report · territory signals, named contacts, and account deep dives

revenuecatalyst.io/intel/[your-territory]-april-2026

All Expansion Net-New HCP / KOL Deep Dive

All Territories T1 T2 T3 T4

Recency ↓ Fit ↓ Size ↓

Sample Output · April 2026

What the Sales Intel Agent delivers

Sample preview · live customer reports run monthly across your full territory list with verified contacts and per-rep deep dives

RC’s Sales Intel Agent is a multi-stage AI pipeline: 25+ live data sources refreshed monthly, LLM-powered ICP fit scoring, expansion + net-new + HCP signal extraction, named contact enrichment, and per-rep territory action plans. Every signal cross-referenced against your CRM, every contact verified, every angle tied to your sales playbook – delivered as a tabbed monthly report your reps can act on without sifting.

Scope: 25+ data sources spanning regulatory filings, job intelligence, financial data, industry news, conference proceedings, and AI-powered deep research returned 142 raw signals across your territories this month; 22 surfaced below carry enough commercial signal on ICP fit, recency, and account priority to warrant your team’s time. Must-Action items flagged where all three align.

Expansion Signals

Growth triggers in existing accounts – new facilities, hiring surges, regulatory milestones

Net-New Prospects

Companies not in your CRM matching your ICP – funding rounds, key hires, market entries

Target HCP / KOL

Key opinion leaders and high-value HCPs – publication history, conference activity, connection paths

Deep Dives

Full account dossiers on priority accounts – named personas, competitive landscape, outreach hooks

Data sources used · 25+ across 6 categories

How to use this

Start at Summary for the month-at-a-glance signal map plus the highest-priority signals across all territories.
Click into any Territory tab for the full list of expansion signals, net-new prospects, HCP / KOL targets, and competitive watches in that territory.
Open Deep Dive for the priority account dossier – 30+ named personas across buying initiatives, competitive landscape, and entry points.
Use the filters in the header above to narrow by signal type, territory, recency, or free-text search across accounts, contacts, and signal narratives.

Summary

Territory 1

Territory 2

Territory 3

Territory 4

Deep Dive

Feedback

Summary · month-at-a-glance across all territories

Top Signals 4 Highest priority across territories · tap a tab for territory detail

1 Worldwide · updated Apr 22 Expansion Opp · XL · Tier-A pharma CA ★ Must-Visit 92% FIT

Genentech / Roche – $50B U.S. investment, 6+ new sites under construction

South San Francisco, CA · expansion across 4 states · 9 named contacts mapped

2 Territory 2 · updated Apr 20 Net-New Opp · L · Biotech MA ★ Must-Visit 87% FIT

Crescent Biopharma – $400M+ Series B, IND cleared Jan 2026

Waltham, MA · first commercial franchise scaling · 4 named contacts mapped

3 Territory 1 · updated Apr 18 HCP / KOL Opp · M · KOL CA 84% FIT

Dr. Sarah Chen – VP Translational Medicine, ASCO 2026 speaker

San Diego, CA · speaking slot confirmed Jun 1 · 2nd-degree warm path

4 Territory 3 · updated Apr 15 Deep Dive Opp · XL · Priority account NY ★ Must-Visit 96% FIT

Regeneron – $14.3B FY25, $2B greenfield + triple bispecific launch

Tarrytown, NY · 9 sites across 2 countries · 30+ named personas mapped across 4 buying initiatives

View all 22 signals · 48 contacts across territories

Geographic Distribution 14 Pulse size = signal weight · color by type

Expansion Net-New HCP / KOL Deep Dive

Conference Intel Agents Conference Intel Report Per-conference report · day-by-day action plan, exhibit-floor heatmap, verified contacts

revenuecatalyst.io/intel/[your-conference]-2026

All New Biz Expansion Competitor ★ Must-Visit

75%+ 50%+ 25%+ Any

All Day AM PM

Fit ↓ Day ↓ Size ↓

Sample Output · AACR 2026

What the Conference Intel Agent delivers

Filtered preview · live customer reports run all 4 days, all tiers, with verified contacts

RC’s Conference Intel Agent is a multi-stage AI pipeline: automated program scraping, LLM-powered commercial scoring, contact enrichment, and day-by-day action-plan generation. Every abstract read, every presenter matched, every action prioritized – in minutes, and compounding across pre-show outreach, on-show execution, and post-show follow-up.

Scope: 34 search queries across core technology, adjacent methodology, target collaborators, and direct competitors returned 286 unique presentations from the AACR 2026 Program Planner; 142 surfaced below carry enough commercial signal on topical fit, target-account priority, and commercial stage to warrant your team’s time. Must-visits flagged where all three align.

Search queries used · 34 across 5 tiers

How to use this

Start at Summary for the week-at-a-glance heatmap plus the highest-fit entries across all days.
Click into any day for the exhibit-floor activity heatmap plus the full list of posters, talks, and competitive entries for that day.
Use the filters in the header above to narrow by fit threshold, tier, or free-text search across titles, abstracts, authors, and institutions.

Summary

Sun

4/19

Mon

4/20

Tue

4/21

Wed

4/22

Competitive

Contacts

Sunday April 19 · 9:00 AM – 5:00 PM

1 of 1 Yours 4 of 27 Posters 0 of 3 Talks 1 of 6 Competitors 76 Contacts

Exhibit Floor Activity · Sunday · Apr 19

Posters 2 Top 2 must-visit posters at 75%+ FIT

1 Abs 1056 · Bd 24 · Sec 41 · Sun 2:00 PM New Business Opp · L · Tier-B pharma NJ ★ Must-Visit 80% FIT

Integrative multi-omics characterization and AI-driven biomarker discovery for NSCLC stage III outcomes

Johnson & Johnson Innovative Medicine – K. Chua & A. Saadatpour · New Brunswick, NJ

Foundation Model KRAS EGFR Lung NSCLC

Why Now

Johnson & Johnson – Tier-B pharma target – is presenting a multimodal AI framework that fuses RNA, DNA, and tumor PD-L1/TMB signals on the PACIFIC trial follow-up (Stage III NSCLC consolidation durvalumab cohort, n = 281 vs 72). They’re calling out STK11 expression and radiosensitivity as new biomarker handles. Active CDx-style partner-shopping signal – J&J owns the patient cohort, the foundation model, and the regulatory path; they need an orthogonal H&E→biomarker validator to scale their per-patient call layer.

Drives 80% FIT = Tier-B pharma + Foundation model + KRAS/EGFR/lung overlap

Your Play

Stop at Section 41, Sun 2:00-5:00. Open with their STK11 + radiosensitivity stratification result and ask which next indication they want to deploy the framework on. Position your platform as the per-cell biomarker layer that turns molecular calls into actionable H&E reads at scale, without incremental tissue. Qualify in 5 min: indications on roadmap, CDx timeline, internal pathology stack. Post-conference: send a co-validation proposal scoped to PACIFIC follow-up or J&J’s next IO indication.

Presenting Author

Katherina C. Chua

Johnson & Johnson, New Brunswick, NJ

LinkedIn ••••• k.chua@ •••• .com

Senior Author

Assieh Saadatpour

Johnson & Johnson, New Brunswick, NJ

LinkedIn ••••• a.saadatpour@ •••• .com

2 Abs 94 · Bd 1 · Sec 5 · Sun 2:00 PM New Business Opp · XL · Tier-A pharma CA MN ★ Must-Visit 77% FIT

Liquid biopsy profiling of the tumor microenvironment to determine response to immunotherapy regimens across solid tumors

Stanford University School of Medicine × Mayo Clinic – E. Brown & A. Chaudhuri · Stanford, CA & Rochester, MN

Spatial Biology Tumor Microenvironment Liquid Biopsy Lung NSCLC

Why Now

Stanford × Mayo – flagship US academic medical centers – built Liquid Ecotyper, an interpretable deep-learning framework that recovers 9 spatial-ecotype profiles (including SE7 ICI-benefit and SE4 ICI-resistance) from cell-free DNA methylation. Validated on 78 melanoma + 25 NSCLC + 10 MIBC ICI-treated patients. Tier-A pharma readiness: a noninvasive spatial-TME biomarker that could replace serial biopsies in IO trials. Active collaborator-shopping signal – multi-institution authorship spanning WashU, Yale, Columbia, Rochester.

Drives 77% FIT = Spatial TME signature + Multi-cohort ICI validation + Stanford / Mayo pull

Your Play

Stop at Section 5, Sun 2:00-5:00. Open with their SE7-vs-SE4 ICI stratification result and ask which trial cohorts they want to deploy Liquid Ecotyper against next. Position your platform as the tissue-side companion that pairs spatial-ecotype calls with per-cell biomarker reads from the same H&E sample. Qualify in 5 min: trial pipeline, Mayo / Stanford site rollout, pharma sponsor list. Post-conference: send a co-validation proposal scoped to NSCLC ICI + the next solid-tumor cohort.

Presenting Author

Erin L. Brown

Stanford University School of Medicine, CA

LinkedIn ••••• e.brown@ •••• .edu

Senior Author

Aadel A. Chaudhuri

Mayo Clinic, Rochester, MN

LinkedIn ••••• a.chaudhuri@ •••• .edu

View all 27 Sun posters · 4 must-visit

Talks 1 Top must-visit talk this week (cross-day spotlight)

3 Minisymposium MS.BCS02.01 · Ballroom 20 CD · Tue 3:20 PM New Business Opp · XL · Tier-A pharma MA ★ Must-Visit Phase 3 82% FIT

AI-derived H&E biomarkers predict differential survival under immunotherapy vs chemotherapy in Phase-3 metastatic NSCLC study NEPTUNE

AstraZeneca Oncology – C. Parmar & D. Palmer · Waltham, MA & Gaithersburg, MD

AI Pathology Tumor Microenvironment NSCLC Immuno-Oncology Phase 3

Why Now

AstraZeneca retrospectively applied an AI-pathology pipeline to 426 H&E slides from NEPTUNE Phase 3 (D+T vs ctx in metastatic NSCLC). Stromal immune density was predictive of D+T benefit (HR 0.64, +5.8 mo OS, p_interaction = 0.03) – outperforming PD-L1 and bTMB stratification. Active CDx / partnership opportunity at registrational scale. AZ owns the slides, owns the pipeline, owns the trial – they need an orthogonal H&E→biomarker partner to scale across the IO portfolio.

Drives 82% FIT = Tier-A pharma + Phase 3 registrational + AI H&E biomarker

Your Play

Catch the talk Tue 3:20 PM in Ballroom 20 CD. Open with their +5.8 mo OS treatment-interaction result and ask which next IO trial they want to deploy the pipeline against. Position your platform as the per-cell biomarker layer that turns their stromal-density signal into actionable per-patient calls. Walk to your booth, qualify in 5 min: indications on roadmap, CDx timeline, internal pathology stack. Post-conference: send a CDx co-development proposal scoped to NSCLC + AZ’s next IO indication.

Presenting Author

Chintan Parmar

Computational Pathology Lead, AstraZeneca, Waltham

LinkedIn ••••• chintan.parmar@ •••• .com

Senior Author

Dean Palmer

AstraZeneca Oncology, Gaithersburg

LinkedIn ••••• dean.palmer@ •••• .com

View all 14 talks this week · 2 must-visit

Competitors 1 Top competitor watch on Sun · same section as your booth

4 Abs 76 · Bd 7 · Sec 4 · Sun 2:00 PM Competitor Threat · L · Direct overlap MA 84% FIT

IHCExplore: An AI-driven computational pathology platform for accurate and scalable immunohistochemistry scoring

PathAI, Inc. – K. Luu & E. Krause · Boston, MA

Computational Pathology Foundation Model (Pluto) IHC Scoring PD-L1 NSCLC

Why Now

PathAI – direct competitor – is presenting IHCExplore, an AI scoring platform built on their Pluto foundation model (24,390 WSIs / 123 staining assays). The proof-of-concept is a PD-L1 TPS validation against 5-pathologist consensus across SP263 / SP142 / 28-8 / 22C3 clones in 597 NSCLC slides – with calibrated thresholds boosting their ICC vs manual review. They are positioning their platform exactly where you are positioning yours: scalable, reproducible IHC scoring for ADC and IO biomarker workflows.

Drives 84% FIT = Same buyer space + Foundation-model overlap + PD-L1 / NSCLC head-on

Counter-Play

Stop at Section 4, Sun 2:00-5:00 (same section as your booth path). Get the specifics on PathAI’s threshold-calibration story and which pharma sponsors are named in the abstract. Counter: your platform delivers a per-cell IHC-equivalent readout from H&E directly, removing the staining step PathAI still requires. Proof: your published ICC vs. their calibrated cutoff. Opener: “If you’re building toward sponsor-grade scoring, the question is whether the assay step is needed at all.” Post-conference: brief your AE / Sales Eng. on co-author affiliations so they can preempt PathAI in any overlapping accounts.

Presenting Author

Kelsey Luu

PathAI, Inc., Boston, MA

LinkedIn ••••• k.luu@ •••• .com

Senior Author

Emma Krause

PathAI, Boston, MA

LinkedIn ••••• e.krause@ •••• .com

View all 6 Sun competitors · 24 across week

Prospecting · Demand Generation · Sales Ops Rev Ops Services Hands-on services that ride alongside the agents – turn the report into pipeline

Prospecting

Net-new outreach campaigns built off the Intel Card. Verified contacts · sequenced messaging · meetings booked.

Demand Generation

Content, paid, and event motions tied to the same ICP signals the agents surface. LinkedIn, conference outreach, nurture sequences.

Sales Ops

CRM hygiene, pipeline analytics, sales-cycle instrumentation. Make sure the signals the agents surface actually move through your funnel.

What We Build, and What It Costs

Transparent pricing. Every engagement starts with your team’s actual needs. Five product lines, one transparent structure – scale at your pace.

Intel Agents

Rev Ops Services

Sales Intel Agents Conference Intel Agents Prospecting Demand Generation Sales Ops

Sales Intel Agents

Monthly Annual Save 20%

One-Time Charge

Mo Yr

Standard

$3,500/mo$33,600/yr

Per product linePer product line – $2,800/mo effective – Save 20%

Monthly interactive HTML report tabbed by territory, hosted on a password-protected URL your team shares without IT setup
Expansion + Net New Prospect Intel Cards across your territories
1 Target Account Deep Dive per month (you pick)
One-click Copy-to-CRM-Note on every card · CSV export of all contacts with rep-assignment column
Tuned monthly from your feedback – gets smarter over time

YOUR LIFT: NEAR ZERO

You bring territory maps, ICP(s), and sales playbook summary. No IT, no security review, zero footprint – all LLM and API costs included.

Mo Yr

Premium

$5,000/mo$48,000/yr

Per product linePer product line – $4,000/mo effective – Save 20%

Everything in Standard
3 Target Account Deep Dives per month (2 additional)
Target HCP / KOL Intel Cards
LinkedIn network matching (optional) – see which contacts your reps already know

YOUR LIFT: NEAR ZERO

Same as Standard, plus rep LinkedIn contacts (or LinkedIn Sales Nav TeamLink access). No IT, no security review, zero footprint – all LLM and API costs included.

One-Time Charge

One-time

Build + Transfer (Advanced)

$25,000 – $35,000

Per product line + $1,500/mo advisory

Full agent stack on your infrastructure
Team training, docs, and IP transfer
Advisory retainer for ongoing tuning
You own the agents and data pipeline

YOUR LIFT: SIGNIFICANT

IT involvement, infrastructure, API keys, and LLM costs. Your team maintains the agent stack post-transfer.

Proof of Concept

$2,500

One-time – credited toward subscription if you continue

Full Standard deliverable in 1 week
Your team works the intel for the rest of the month
Yours to keep beyond the PoC

YOUR LIFT: NEAR ZERO

Same as Standard – territory maps, ICP(s), sales playbook summary. All LLM and API costs included. Get a real deliverable in your hands before committing.

Get Started

Conference Intel Agents

Single Conference

$1,500

Per product line

Interactive HTML action plan tabbed by conference day, hosted on a password-protected URL your team shares without IT setup
Poster hit list + named contacts
Competitive intel overlay
Marketing mailer content

YOUR LIFT: NEAR ZERO

You bring product line + competitive landscape (1-pager), target accounts, booth number + team schedule. We deliver the action plan before you land.

3-Pack

$3,750

Per product line – Use within 12 months

Everything in Single Conference
Cover your top 3 conferences this year
Consistent formatting across events
Cumulative competitive tracking

YOUR LIFT: NEAR ZERO

Same as Single, plus your top 3 conferences for the year. We build institutional memory – patterns compound across events.

5-Pack

$5,000

Per product line – Use within 12 months

Everything in Single Conference
Full-year coverage for heavy conference teams
Priority scheduling during peak season
Cross-conference trend analysis

YOUR LIFT: NEAR ZERO

You bring annual conference calendar at the start. We handle priority scheduling and cross-conference trend analysis.

Sales Intel Agents Subscribers Save 20%

Active Sales Intel Agent subscribers (Standard or Premium) receive 20% off any conference package.

Get Started

Prospecting

Prospecting Engagement

Project-based or fractional retainer

Scoped to your ICP, channels, and campaign goals

Publication-matched targeting + KOL identification (NPI, SciLeads, your subscriptions)
Multi-channel campaigns (email, LinkedIn, phone) on proven HCLS playbooks
Real-time engagement dashboards + MQL/SQL routing
Full infrastructure: domain warm-up, deliverability, sequencing tools

YOUR LIFT: MODERATE

You bring ICP + target account list, email domain access for warm-up, sales process / hand-off rules for MQLs.

Get Started

Demand Generation

Demand Generation Engagement

Project-based or fractional retainer

Scoped to your campaigns, channels, and growth targets

Technical content for HCLS audiences (app notes, workflow guides, campaign pages)
Pre/post-conference outbound tied to specific events (AACR, ASCO, SLAS, ASHG)
Google + LinkedIn advertising tuned for scientific search and researcher audiences
Marketing automation: lead scoring, nurture, MQL routing (HubSpot/Marketo/Pardot)
SEO + website optimization: landing pages, forms, conversion tracking

YOUR LIFT: MODERATE

You bring brand assets + product positioning, marketing automation platform seat (HubSpot/Marketo/Pardot), sales hand-off rules for MQLs.

Get Started

Sales Operations

Sales Ops Engagement

Project-based or fractional retainer

Scoped to your CRM, pipeline, and reporting needs

Full CRM build, migration, automation (Salesforce, HubSpot, Veeva, Dynamics)
Forecasting dashboards: commit, best case, pipeline, deal velocity
Territory planning, lead scoring, account segmentation
Sales process docs, onboarding playbooks, rep ramp programs
CS + renewal dashboards: customer health, expansion signals, churn risk

YOUR LIFT: MODERATE

You bring CRM admin access (or willingness to grant), historical sales + customer data, stakeholder alignment on KPIs.

Get Started

Client Results

Outcomes from HCLS commercial teams. From first engagement to measurable impact – case studies and metrics from active customers.

VC-Backed Single-Cell Biotech

Sales Pipeline from Zero to 43 Opportunities

43 Qualified Opps 2x $100K Orders in 60 Days In 2.5 Months

“Created a significant sales funnel from scratch, in a scalable and trainable way which allowed our team to take over and continue growing it independently.”

– Co-Founder & CSO

Hover front for stats

AI Medical Scribe Platform

From No CRM to Full Pipeline Visibility

Deal Velocity Tracking Revenue Forecasting 3 Team Dashboards

“Gave us a foundation from which to measure performance, in general and more systematically, which helped us understand foundational dynamics with regard to sales performance, deal velocity, and forecasting.”

– SVP & Head of Sales

Hover front for stats

Microfluidic Flow Cytometry

40% Revenue Growth, 3 Sales Hires Onboarded

40% YOY Growth 3 Reps Hired & Trained On Scope & Budget

“Best in class for our small size company. On scope, on time, on budget.”

– VP Commercial

Hover front for stats

Protein Analysis Technology

56% Open Rate, 2.4x Industry Average

56% Open Rate 2,400 Publication-Matched Leads 4 Orders Won

2,400 validated leads from evidence-matched scientific publications. 5-email sequence ramped to 100 daily sends. 4 order submissions including 1 new customer.

– Co-Founder & CEO

Hover front for stats

Life Science Tools Company

6 Campaigns Drove 19.2% of All Website Traffic

3,246 Campaign Sessions 79% New Visitors 6 Campaign Pages

6 linked campaign pages driving 3,246 sessions. Top performer: Live Cell Painting (1,252 sessions). CTA pages: Shop (614 sessions), Contact Us (204 sessions).

– Head of Marketing

Hover front for stats

The Team

Operators who lived these problems. We carried the bag, managed the territory, and built the systems before we built the agents.

Trey Knollman

Founder & AI Agent Architect

Seattle, WA

18 years inside HCLS companies spanning bench to boardroom. Scientist at OHSU and Thermo Fisher (8+ peer-reviewed publications), then commercial leader through Essen BioScience (acquired by Sartorius for $320M), IntelliCyt (acquired by Sartorius for $90M), IsoPlexis ($111M IPO), and Amplion (acquired by Science & Medicine Group). Built and led teams that hit 147% of quota, drove 40% YOY revenue growth at NanoCellect, and took products from zero to market across flow cytometry, single-cell, genomics, and diagnostics. Architected GTM tech stacks delivering 20x return on marketing spend, ran 1.1M-email outbound engines hitting 300% of lead gen goal, and managed $20M+ regional P&Ls. Now builds the AI agents and data pipelines that produce RC’s Intel Cards – hands-on across Python, HTML, Salesforce, HubSpot, and GCP.

Flow cytometry, single-cell analysis, genomics/proteomics, diagnostics, digital health, SaaS

LinkedIn →

Sohiel Memarsadeghi

Partner & Technical Architect

San Francisco, CA

Biomedical engineer with 25 years across the full product lifecycle spanning R&D, engineering, manufacturing, program management, and technical sales. Drove the introduction of four category-defining instrument platforms – FLIPR, IonWorks HT, IncuCyte, and NX One – at Molecular Devices, Essen BioScience (acquired by Sartorius for $320M), and Nodexus. Built deep customer relationships and KOL partnerships through value-driven technical sales across key pharma (AbbVie, Amgen, BMS, Genentech, Gilead, Pfizer, Vertex) and academic institutions. Conducted the first proof-of-concept high-throughput profiling of ion channel activity in human blood cells with potential utility for early disease diagnosis and monitoring of autoimmune disorders. Led the development and execution of the inaugural Interdisciplinary Life Sciences program at the University of San Francisco with industry-sponsored projects for undergraduate students.

Live-cell analysis, drug discovery assays, GPCR screening, high-throughput electrophysiology, ion channel pharmacology, single-cell workflows, translational research, microfluidics

LinkedIn →

Let’s Talk

Start here. Whether you need an AI agent, a full commercial engine, or want to explore what is possible – we will reach out within 24 hours.

Start a Conversation →

AI Agents & Revenue Operations for Healthcare and Life Sciences

Built by HCLS operators with deep domain expertise spanning IC to VP across sales, marketing, and customer success – we have lived the problems these agents and services solve.

Why Now

One agentic pipeline replaces dozens of manual searches

Science-matched targeting changes the math

The window for first-mover advantage is now

What is an Intel Card?

Crescent Biopharma

Genentech / Roche

Crescent Biopharma

Dr. Sarah Chen, MD, PhD

Regeneron Pharmaceuticals

AI Agents and Services

Your Autonomous Intelligence Pipeline

What We Build, and What It Costs

Standard

Premium

Build + Transfer (Advanced)

Proof of Concept

Single Conference

3-Pack

5-Pack

Prospecting Engagement

Demand Generation Engagement

Sales Ops Engagement

Client Results

Sales Pipeline from Zero to 43 Opportunities

From No CRM to Full Pipeline Visibility

40% Revenue Growth, 3 Sales Hires Onboarded

56% Open Rate, 2.4x Industry Average

6 Campaigns Drove 19.2% of All Website Traffic

The Team

Trey Knollman

Sohiel Memarsadeghi

Frequently Asked Questions

Let’s Talk

Let’s Talk

AI Agents & Revenue Operations
for Healthcare and Life Sciences